Technology

How to Implement an ePRO Strategy

Mukhtaer Ahmed outlines how advances in machine-to-machine (M2M) technologies have the potential to transform clinical development programs, including clinical trials.

Are electronic health records a viable channel for engagement? Ben Comer reports.

Product labeling

How vulnerable is Big Pharma to the predations of organized terrorist groups or that rogue malcontent with an agenda to wreak havoc on society?

Pharmacovigilance in a box

Led by two New Yorkers with a mindset that marries novel scientific insights to the processing power of novel technologies, Regeneron's success is a revolutionary challenge to the industry status quo.

For the hard-pressed oncology practice, new technologies hold the key to surviving-and thriving.

Improving the quality of clinical trials is a major strategic activity for Big Pharma, one where efficient management of a demanding set of regulatory requirements can have a positive impact on the bottom line.

Innovation in hub program design for patient scrip data and clinical support services can lead to increased market share in the hotly contested specialty medicine space.

Ben Comer profiles 10 innovative technologies designated as new and revolutionary tools for the treatment of disease and disability.

If we swallow the hype and decide that we all need to get onto the mobile app bandwagon, how exactly do we go about it? Sven Awege explains.

Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures.

Sciformix's Integrated Drug Safety solution seamlessly interweaves and synchronizes services across all phases of the product lifecycle.

Cegedim Relationship Management held its annual conference on trends in the life sciences industry last week.

“Doctor’s don’t hate technology, they hate bad technology,” said Shane Kennedy, managing director, digital, at Sudler & Hennessey.

Planning for the long term is increasingly seen as an abstract absurdity. But a lasting business model is still possible-if you learn to adapt.

As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.

Sciformix white paper

Why, with all the data available, is pharma so bad at getting true marketing insights to drive its business? Bill Drummy looks at how to realize the promise of "Big Data".

It may surprise some working in the industry, but pharmaceutical companies, in particular those in Europe, rank among the world’s best online corporate communicators, writes David Bowen.

Since its launch two years ago, the iPad has enjoyed unprecedented success in the healthcare space. But how long can the technology captivate physicians? Dan Goldsmith and Paul Shawah report.

Recruitment

The EDQM are looking to recruit a Scientific Programme Officer to join the team in co-ordinating and running mutual joint visits and audits of laboratories within the Official Medicines Control Laboratories (OMCLs) for a five year duration.

Early efforts in the pharma space to harness the engagement factor in game technology focused on delivering a fun experience, with a tackedon educational component. Today's games bring behavior change to the forefront, incorporating social dynamics, mobility, and increasingly sophisticated mechanics.

Industry's ability to master the external environment depends on making the 140-character shorthand of the Twitter generation its own.

Options for using data have proliferated to the point of becoming overwhelming. So what opportunities does this information explosion present?

Highlighting the companies awarded for exemplifying a high level of operational excellence with technology.

Defining and using quality metrics for adverse events case processing.

This year's Ad Stars embrace creativity through the eyes of the patients. Ben Comer and Jennifer Ringler report.